VANCOMYCIN 500 MG VIAL
For 1 unit (EA)
Pharmacies pay
$2.31 filed
1 × $2.3054 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-12-17 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part B pays
$1.60 derived
1 × $1.60 per EA, Part B limit
Medicare's price is not your price.
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
The spread
0.69× estimated
Medicare pays 31% less than pharmacies pay.
15 labelers share HCPCS J3373 on the CMS crosswalk, so its payment limit is an average across all their products billed under that code, not this NDC’s own price.
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2025-12-17 (file of 2026-10-14, retrieved 2026-10-17) · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
Cost-plus estimate
$7.66 estimated
$2.31 + $0.35 (15%) + $5.00 fee per fill = $7.66
This is a model, not a price any pharmacy quoted. Shipping is not included. For a pack this cheap, the $5.00 fee is most of the estimate. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2025-12-17 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
VANCOMYCIN 500 MG VIAL is how the CMS NADAC file names this product. The FDA NDC Directory lists it as vancomycin hydrochloride.
FDA gives its dosage form as injection, powder, lyophilized, for solution and its route as intravenous.
FDA lists 7 labelers (the companies named on the label) for its NDCs, among them Hospira, Inc., Sagent Pharmaceuticals and Camber Pharmaceuticals, Inc.
FDA’s Established Pharmacologic Class for it is Glycopeptide Antibacterial.
The NADAC file of 2026-10-14 prices it under 8 NDCs (National Drug Codes); the FDA directory lists 7 of them.
NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $2.31 for 1 unit (EA) (1 × $2.3054 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2025-12-17. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.
The NADAC of all 8 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2025-12-17. The file is new; the price is not.
What NADAC measures · NADAC explanation codes · Carried-forward prices
The 7 labelers
| Labeler | NDCs | Pharmacies pay per unit |
|---|---|---|
| Camber Pharmaceuticals, Inc. | 1 | $2.3054 per EA filed |
| Hospira, Inc. | 1 | $2.3054 per EA filed |
| Meitheal Pharmaceuticals Inc. | 1 | $2.3054 per EA filed |
| Mylan Institutional LLC | 1 | $2.3054 per EA filed |
| Sagent Pharmaceuticals | 1 | $2.3054 per EA filed |
| Slate Run Pharmaceuticals, LLC | 1 | $2.3054 per EA filed |
| Xellia Pharmaceuticals USA LLC | 1 | $2.3054 per EA filed |
| Not listed as a package in the FDA directory | 1 | $2.3054 per EA filed |
All 8 NDCs, with labeler and price
- 00409-4332-01 · Hospira, Inc. · $2.3054 per EA · eff. 2025-12-17 filed carried forward
- 25021-0150-10 · Sagent Pharmaceuticals · $2.3054 per EA · eff. 2025-12-17 filed carried forward
- 31722-0210-10 · Camber Pharmaceuticals, Inc. · $2.3054 per EA · eff. 2025-12-17 filed carried forward
- 67457-0339-50 · Mylan Institutional LLC · $2.3054 per EA · eff. 2025-12-17 filed carried forward
- 70436-0020-82 · Slate Run Pharmaceuticals, LLC · $2.3054 per EA · eff. 2025-12-17 filed carried forward
- 70594-0045-02 · not listed as a package in the FDA directory · $2.3054 per EA · eff. 2025-12-17 filed carried forward
- 70594-0122-02 · Xellia Pharmaceuticals USA LLC · $2.3054 per EA · eff. 2025-12-17 filed carried forward
- 71288-0022-11 · Meitheal Pharmaceuticals Inc. · $2.3054 per EA · eff. 2025-12-17 filed carried forward
Other strengths, forms and brands
6 other products in the NADAC file share the FDA nonproprietary name vancomycin hydrochloride with VANCOMYCIN 500 MG VIAL.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| FIRVANQ 50 MG/ML SOLUTION | $1.18602 per ML filed | $0.92382 per ML filed |
| VANCOMYCIN 25 MG/ML ORAL SOLN | $0.39002 to $0.67288 per ML filed | We don’t know yet |
| VANCOMYCIN 50 MG/ML ORAL SOLN | $0.70181 to $0.8007 per ML filed | We don’t know yet |
| VANCOMYCIN 250 MG/5 ML ORAL SOL | $0.70181 to $2.90936 per ML filed | We don’t know yet |
| VANCOMYCIN 500 MG VIAL this page | $2.3054 per EA filed | $1.60 per EA derived |
| VANCOMYCIN HCL 125 MG CAPSULE | $1.32898 per EA filed | We don’t know yet |
| VANCOMYCIN HCL 250 MG CAPSULE | $2.59757 per EA filed | We don’t know yet |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-12-17, 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
What Medicare paid
Medicare Part B’s payment limit for HCPCS J3373, for 2026-10-01 to 2026-12-31, comes to $1.60 for 1 unit (EA), or $1.60 per EA once converted to NADAC’s unit for this product.
Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.
The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.0064 per 10 MG.
6 of the product’s 8 NDCs have this Medicare figure; the other 2 do not, and the interactive card says why for each.
Medicare's price is not your price.
What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
- If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why does this page start at 1 unit (EA)?
- NADAC prices this product per EA, and the FDA NDC Directory lists 7 of its 8 NDCs (it does not list the other one) as dosage form “INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION” with route “INTRAVENOUS”. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and none of these is one. NADAC’s EA for it may be a whole package (such as a kit, pen, syringe, vial or inhaler) or one dose inside it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.